Literature DB >> 11245469

End-joining deficiency and radiosensitization induced by gemcitabine.

K Smid, G J Peters, H H Kampinga.   

Abstract

The mechanism of radiosensitization by gemcitabine (2',2'-difluoro-2'-deoxycytidine, dFdC) is not exactly known. We investigated the possible role of inhibition of the repair of DNA double-strand breaks by dFdC by measuring the extent of radiosensitization in different cell lines deficient and proficient in components of nonhomologous end-joining and in the parental cell lines. Different cell lines were incubated with 0.5 and 5 microM dFdC for 4 h. Cells deficient in DNA-dependent protein-kinase catalytic subunit (V3) showed sensitization similar to that of wild-type cells (AAS) and complemented cells (V3+YAC). Ku80-deficient cells (xrs5 and xrs6) showed even more radiosensitization by dFdC as compared with wild-type CHO-K1. However, Ku80-complemented cell lines (xrs5+huKu80 and xrs6+haKu80) did not show radiosensitization. The differences in dFdC-mediated radiosensitization were not attributable to different changes in deoxynucleotide triphosphate levels and cell cycle distribution. We conclude that a functional nonhomologous end-joining pathway is not required for dFdC-mediated radiosensitization.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11245469

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  14 in total

1.  Drug metabolism and homologous recombination repair in radiosensitization with gemcitabine.

Authors:  Michael M Im; Sheryl A Flanagan; Jeffrey J Ackroyd; Donna S Shewach
Journal:  Radiat Res       Date:  2015-01-07       Impact factor: 2.841

2.  Effect of gemcitabine on the expression of apoptosis-related genes in human pancreatic cancer cells.

Authors:  Pei-Hong Jiang; Yoshiharu Motoo; Norio Sawabu; Toshinari Minamoto
Journal:  World J Gastroenterol       Date:  2006-03-14       Impact factor: 5.742

3.  Colour junctions as predictors of radiosensitivity: X-irradiation combined with gemcitabine in a lung carcinoma cell line.

Authors:  Natasja Castro Kreder; Chris Van Bree; Nicolaas A P Franken; Jaap Haveman
Journal:  J Cancer Res Clin Oncol       Date:  2003-08-29       Impact factor: 4.553

Review 4.  Improving gemcitabine-mediated radiosensitization using molecularly targeted therapy: a review.

Authors:  Meredith A Morgan; Leslie A Parsels; Jonathan Maybaum; Theodore S Lawrence
Journal:  Clin Cancer Res       Date:  2008-11-01       Impact factor: 12.531

5.  In vitro study on the schedule-dependency of the interaction between pemetrexed, gemcitabine and irradiation in non-small cell lung cancer and head and neck cancer cells.

Authors:  An Wouters; Bea Pauwels; Filip Lardon; Greet G O Pattyn; Hilde A J Lambrechts; Marc Baay; Paul Meijnders; Jan B Vermorken
Journal:  BMC Cancer       Date:  2010-08-19       Impact factor: 4.430

6.  Quantitative estimation of DNA damage by photon irradiation based on the microdosimetric-kinetic model.

Authors:  Yusuke Matsuya; Yosuke Ohtsubo; Kaori Tsutsumi; Kohei Sasaki; Rie Yamazaki; Hiroyuki Date
Journal:  J Radiat Res       Date:  2014-02-09       Impact factor: 2.724

7.  Cell-interdependent cisplatin killing by Ku/DNA-dependent protein kinase signaling transduced through gap junctions.

Authors:  Ryan Jensen; Peter M Glazer
Journal:  Proc Natl Acad Sci U S A       Date:  2004-04-06       Impact factor: 11.205

8.  The relation between deoxycytidine kinase activity and the radiosensitising effect of gemcitabine in eight different human tumour cell lines.

Authors:  Bea Pauwels; Annelies E C Korst; Greet G O Pattyn; Hilde A J Lambrechts; Juliette A E Kamphuis; Christel M J De Pooter; Godefridus J Peters; Filip Lardon; Jan B Vermorken
Journal:  BMC Cancer       Date:  2006-05-30       Impact factor: 4.430

9.  A phase I trial of weekly gemcitabine and concurrent radiotherapy in patients with locally advanced pancreatic cancer.

Authors:  M Ikeda; S Okada; K Tokuuye; H Ueno; T Okusaka
Journal:  Br J Cancer       Date:  2002-05-20       Impact factor: 7.640

10.  The technical feasibility of an image-guided intensity-modulated radiotherapy (IG-IMRT) to perform a hypofractionated schedule in terms of toxicity and local control for patients with locally advanced or recurrent pancreatic cancer.

Authors:  Seok Hyun Son; Jin Ho Song; Byung Ock Choi; Young-Nam Kang; Myung Ah Lee; Ki Mun Kang; Hong Seok Jang
Journal:  Radiat Oncol       Date:  2012-12-05       Impact factor: 3.481

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.